You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization
|
|---|---|
| Published in |
International Journal of Pharmaceutics, November 2017
|
| DOI | 10.1016/j.ijpharm.2017.11.051 |
| Pubmed ID | |
| Authors |
Ken Howick, Ryan Alam, Barbara Chruscicka, Dalia Kandil, Dara Fitzpatrick, Aoife M. Ryan, John F. Cryan, Harriët Schellekens, Brendan T. Griffin |
| Abstract |
There is an impetus to provide appropriate sustained release oral delivery vehicles to protect biofunctional peptide loads from gastric degradation in vivo. This study describes the generation of a high load capacity pellet formulation for sustained release of a freely water-soluble dairy-derived hydrolysate, FHI-2571. The activity of this novel peptidic ghrelin receptor agonist is reported using in vitro calcium mobilization assays. Conventional extrusion spheronization was then used to prepare peptide-loaded pellets which were subsequently coated with ethylcellulose (EC) film coats using a fluid bed coating system in bottom spray (Wurster) mode. Aqueous-based EC coating dispersions produced mechanically brittle coats which fractured due to osmotic pressure build-up within pellets in simulated media. In contrast, an ethanolic-based EC coating solution provided robust, near zero-order release in both USP Type 1 and Type 4 dissolution studies. Interestingly, the functionality of aqueous-based EC film coats was restored by first layering pellets with a methacrylic acid copolymer (MA) subcoat, thereby hindering pellet core swelling in acidic media. Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) was utilised as a complementary technique to confirm the results seen in USP dissolution studies. Retention of activity of the ghrelinergic peptide hydrolysate in the final encapsulated product was confirmed as being greater than 80%. The described pellet formulation is amenable to oral dosing in small animal studies in order to assess in vivo efficacy of the whey-derived ghrelinergic hydrolysate. In more general terms, it is also suitable as a delivery vehicle for peptide-based bioactives to special population groups e.g paediatric and geriatric. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 7 | 50% |
| United States | 1 | 7% |
| Canada | 1 | 7% |
| Switzerland | 1 | 7% |
| Unknown | 4 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 64% |
| Scientists | 4 | 29% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 15% |
| Student > Bachelor | 5 | 13% |
| Lecturer | 4 | 10% |
| Student > Master | 4 | 10% |
| Student > Doctoral Student | 3 | 8% |
| Other | 8 | 20% |
| Unknown | 10 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 20% |
| Agricultural and Biological Sciences | 5 | 13% |
| Medicine and Dentistry | 3 | 8% |
| Engineering | 3 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 13 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2018.
All research outputs
#4,355,211
of 25,382,440 outputs
Outputs from International Journal of Pharmaceutics
#795
of 8,180 outputs
Outputs of similar age
#85,782
of 445,887 outputs
Outputs of similar age from International Journal of Pharmaceutics
#10
of 89 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,180 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,887 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.